Previous studies have suggested that mineralocorticoid receptor antagonist could ameliorate endothelial dysfunction in the setting of heart failure, diet-induced obesity, and a streptozocin-induced diabetic model. This evidence concerns the gene NR3C2 and obesity due to melanocortin 4 receptor deficiency.